Methamphetamines

Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD

Retrieved on: 
Monday, July 12, 2021
Psychoactive drugs, Drugs, Entheogens, Euphoriants, MDMA, Methamphetamines, Stimulants, Post-traumatic stress disorder, Food and Drug Administration, Therapy, Multidisciplinary Association for Psychedelic Studies, Treatments for PTSD

This studyhas advanced through the pre-implementation stage at Numinus' Vancouver clinic and has now received the required federal regulatory approval.

Key Points: 
  • This studyhas advanced through the pre-implementation stage at Numinus' Vancouver clinic and has now received the required federal regulatory approval.
  • During the study, research, medical and therapist staff at Numinus will collectdata on the safety and effectiveness of MDMA-assisted therapyto informHealth Canada andsupport making MDMA-assisted therapy available toindividuals living with PTSD in Canada.
  • "Health Canada should be recognized for its ongoing leadership through its support of this study," said Dr. Christie.
  • These statements are no guarantee of future Health Canada or FDA approval or availability of MDMA-assisted therapy.

The MDMA Conference: A Molecular Masterclass Presents a Scientific Deep Dive into the Field of MDMA Therapeutics

Retrieved on: 
Monday, June 14, 2021
Psychoactive drugs, Drugs, Euphoriants, Entheogens, MDMA, Methamphetamines

Ranging from exploring the cultural implications of MDMA through to its clinical applications, the conference will seek to educate attendees on the potential uses and benefits attached to MDMA in a clinical environment.

Key Points: 
  • Ranging from exploring the cultural implications of MDMA through to its clinical applications, the conference will seek to educate attendees on the potential uses and benefits attached to MDMA in a clinical environment.
  • The event, which will present a scientific deep dive into the dynamic field of MDMA therapeutics, will explore the potential of MDMA at the intersection of drug development & safety, clinical care and applications, law & regulation, business & markets, science & research as well as history & culture.
  • This years event will feature a series of six keynote presentations and discussion panels, to be held over the course of the one-day event.
  • Additional information about the MDMA Conference, as well as details for registration, can be found on the MDMA Conference website at https://microdose.buzz/shop/molecular-masterclass/mdma-conference/ .

2021 Global Methylamine Hydrobromide (CAS 6876-37-5) Market Research Report - Downstream Industry Trends - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 8, 2021
Chemicals, Plastics, Manufacturing, Psychoactive drugs, Drugs, Receptor agonists, Entheogens, Euphoriants, MDMA, Methamphetamines, Stimulants, Hydrobromide, Methylamine

The "Methylamine hydrobromide (CAS 6876-37-5) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Methylamine hydrobromide (CAS 6876-37-5) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Methylamine hydrobromide.
  • The Methylamine hydrobromide global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Methylamine hydrobromide market trends and forecast, distinguish Methylamine hydrobromide manufacturers and suppliers.

MindMed Announces the Publication of New Data on Personalized MDMA Dosing

Retrieved on: 
Monday, April 5, 2021
Psychoactive drugs, Substituted amphetamines, Euphoriants, Stimulants, Entheogens, MDMA, Methamphetamines, 1,3-Benzodioxolylbutanamine

This study provides the first scientific data for predicting responses to MDMA and optimizing dosing.

Key Points: 
  • This study provides the first scientific data for predicting responses to MDMA and optimizing dosing.
  • Women and men showed comparable MDMA effects if differences in body weight are considered in the dosing of MDMA.
  • Previous minimal MDMA use, defined as previously using MDMA up to five times, did not influence the MDMA effect.
  • In summary, personalizing MDMA dosing may help optimizethe acute MDMA experience including more positive subjective effects of MDMA and reducing adverse effects of MDMA.